Clinical impact of EUS and EUS-FNA of bilateral adrenal glands in patients with potentially resectable lung cancer

Clinical impact of EUS and EUS-FNA of bilateral adrenal glands in patients with potentially resectable lung cancer - EUS-FNA of bilateral adrenal glands in lung cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007583

Enrollment

150

Registered

2012-04-01

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consecutive patients with potentially resectable lung cancer who underwent EUS/EUS-FNA for staging of lung cancer at the Gifu University Hospital between October 2009 and September 2011.

Exclusion criteria

Exclusion criteria: The exclusion criteria were patients with poor medical conditions of grades 4 and 5 according to the American Society of Anesthesiologists Physical Status classification system, and patients with bleeding tendency and coagulopathy.

Design outcomes

Primary

Measure	Time frame
To assess the detection rate of right adrenal gland by EUS and to compare the accuracy between CT, PET-CT and EUS/EUS-FNA for adrenal metastases.	—

Secondary

Measure	Time frame
To compare the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) between CT, PET-CT and EUS/EUS-FNA for adrenal metastases. To evaluate the incidence of EUS/EUS-FNA related complications.	—

Countries

Japan

Contacts

Public ContactShinya Uemura

Gifu University Hospital First Dept. of Internal Medicine

ueshin550621@gmail.com058-230-6308

Outcome results